Dr. Grace E. Colón has over 25 years of experience in biopharma, genomics, diagnostics, health care and industrial biotechnology, in both strategic and operational roles with leading public and private companies and as a management consultant at McKinsey. Her executive roles have spanned a broad range of functions, including corporate development/alliance management, commercial strategy and R&D. She is currently a partner at New Science Ventures, a New York-based venture capital firm with $400M under management invested in life science and information technology companies. She is also CEO of InCarda Therapeutics (a developer of cardiovascular therapies which recently raised a $6M Series A) and of ProterixBio, Inc. (a disease management and diagnostics company focused on pulmonary disorders), and serves on the boards of directors at PerceptiMed and Pyranose Biotherapeutics (which she co-founded). Previously she was President of the Industrial Products Division and Senior Vice President at Intrexon Corporation and held several senior leadership roles at Gilead Sciences and Affymetrix. While at Affymetrix, she was also founding Chief Operating Officer of the International Genomics Consortium. Earlier in her career Grace worked at McKinsey & Company, where she served clients in Healthcare, High Tech, Consumer Goods and Venture Capital. She was also an engineer with Merck & Co. in France. Grace holds a B.S. degree in Chemical Engineering from the University of Pennsylvania and a Ph.D. in Chemical Engineering (with a focus on biochemical engineering) from the Massachusetts Institute of Technology.
New Science Ventures